RNAZ (TransCode Therapeutics) Forward Dividend Yield %: 0.00% (As of Jun. 26, 2026)


RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $4.84
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Forward Dividend Yield %?

TransCode Therapeutics RNAZ +10.69% 34 Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 146 Biotechnology companies, TransCode Therapeutics ranks worse than 684930.82% on this metric.

As of today (2026-06-26), the Forward Annual Dividend Yield of TransCode Therapeutics is 0.00%.

As of today (2026-06-26), the Trailing Annual Dividend Yield of TransCode Therapeutics is 0.00%.

RNAZ's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525
* Ranked among companies with meaningful Forward Dividend Yield % only.

TransCode Therapeutics's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

TransCode Therapeutics  (NAS:RNAZ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

TransCode Therapeutics Forward Dividend Yield % Related Terms

RNAZ vs ARTL, GLMD, DCOY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, TransCode Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's Forward Dividend Yield % falls into.


RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
TransCode Therapeutics (RNAZ) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TransCode Therapeutics and its competitors. According to the industry distribution chart, TransCode Therapeutics ranks #999999 out of 146 companies in the Biotechnology industry.
Is TransCode Therapeutics' Forward Dividend Yield % too high?
TransCode Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, TransCode Therapeutics ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Forward Dividend Yield % compare to ARTL and GLMD?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #999999 out of 146 companies for Forward Dividend Yield %. This places TransCode Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TransCode Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransCode Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84
Price